Kyowa Hakko suffers on cancer drug flop despite AstraZeneca deal news
Japanese biotech Kyowa Hakko Kirin (TYO: 4151) closed 1% down after Monday’s trading in Tokyo following the announcement of disappointing trial results.
Shares in the company were worth 1% less, at 1,748 yen, after news that a Phase III trial of tivantinib (ARQ 197), an oral agent whose molecular target is c-MET, failed to meet its primary endpoint.
The JET-HCC trial is a randomized, double-blind placebo-controlled study in Japan involving around 190 subjects, to evaluate the efficacy and safety of tivantinib in the patients with c-Met diagnostic-high inoperable hepatocellular carcinoma with a history of prior sorafenib therapy.
Its primary endpoint is progression-free survival (PFS), and the top-line results did not show a significant difference in PFS between the tivantinib group and those given placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze